Placebo + SPN-812

Phase 3Completed

0 views this week 0 watching💤 Quiet

Interest: 34/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Attention-Deficit/Hyperactivity Disorder (ADHD)

Conditions

Attention-Deficit/Hyperactivity Disorder (ADHD)

Trial Timeline

Nov 20, 2019 → Oct 10, 2020

NCT ID

NCT04016779

About Placebo + SPN-812

Placebo + SPN-812 is a phase 3 stage product being developed by Supernus Pharmaceuticals for Attention-Deficit/Hyperactivity Disorder (ADHD). The current trial status is completed. This product is registered under clinical trial identifier NCT04016779. Target conditions include Attention-Deficit/Hyperactivity Disorder (ADHD).

What happened to similar drugs?

8 of 10 similar drugs in Attention-Deficit/Hyperactivity Disorder (ADHD) were approved

Approved (8) Terminated (0) Active (2)

✅atomoxetineEli LillyApproved

✅AtomoxetineEli LillyApproved

✅Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) + PlaceboNovartisApproved

✅SPN-812Supernus PharmaceuticalsApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04016779	Phase 3	Completed	Nov 20, 2019	Oct 10, 2020	Attention-Deficit/Hyperactivity Disorder (ADHD)

Competing Products

18 competing products in Attention-Deficit/Hyperactivity Disorder (ADHD)

See all competitors

Product	Company	Stage	Hype Score
atomoxetine	Eli Lilly	Approved	39
Atomoxetine	Eli Lilly	Approved	43
Atomoxetine	Eli Lilly	Approved	43
Atomoxetine	Eli Lilly	Approved	43
ABT-089 + atomoxetine + placebo	AbbVie	Phase 2	35
ABT-089 + Placebo	AbbVie	Phase 2	35
ABT-089	AbbVie	Phase 2	35
ABT-089 + placebo	AbbVie	Phase 2	35
MK0249 + Concerta (methylphenidate) + Placebo	Merck	Phase 2	35
Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) + Placebo	Novartis	Approved	43
SPN-812	Supernus Pharmaceuticals	Approved	37
IR Viloxazine + Placebo	Supernus Pharmaceuticals	Phase 1/2	26
SPN-812	Supernus Pharmaceuticals	Approved	37
100mg SPN-812 + Placebo	Supernus Pharmaceuticals	Approved	44
SPN-812	Supernus Pharmaceuticals	Phase 3	34
Placebo + 100mg SPN-812 + 200mg SPN-812 + 300mg SPN-812 + 400mg SPN-812	Supernus Pharmaceuticals	Phase 2	29
SPN-812	Supernus Pharmaceuticals	Phase 3	38
TD-9855 + TD-9855 + Placebo	Theravance Biopharma	Phase 2	29